{"id":"https://openalex.org/W978267315","doi":"https://doi.org/10.1007/s00280-015-2824-6","title":"A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors","display_name":"A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors","publication_year":2015,"publication_date":"2015-07-25","ids":{"openalex":"https://openalex.org/W978267315","doi":"https://doi.org/10.1007/s00280-015-2824-6","mag":"978267315","pmid":"https://pubmed.ncbi.nlm.nih.gov/26210681"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-015-2824-6","doi":"https://doi.org/10.1007/s00280-015-2824-6","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-015-2824-6","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079943316","display_name":"Haby Adel Henary","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Henary","raw_affiliation_strings":["Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030273391","display_name":"Goldy Chacko George","orcid":"https://orcid.org/0000-0002-1966-876X","observed_orcids":["https://orcid.org/0000-0002-1966-876X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. C. George","raw_affiliation_strings":["Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036211173","display_name":"Jennifer J. Wheler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Wheler","raw_affiliation_strings":["Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011494177","display_name":"A. Naing","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Naing","raw_affiliation_strings":["Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026538331","display_name":"Sarina Anne Piha-Paul","orcid":"https://orcid.org/0000-0001-9455-1660","observed_orcids":["https://orcid.org/0000-0001-9455-1660"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Piha-Paul","raw_affiliation_strings":["Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045197829","display_name":"Siqing Fu","orcid":"https://orcid.org/0000-0002-1933-0419","observed_orcids":["https://orcid.org/0000-0002-1933-0419"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Fu","raw_affiliation_strings":["Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075427253","display_name":"Reena Mistry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Mistry","raw_affiliation_strings":["Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105167216","display_name":"Ralph Zinner","orcid":"https://orcid.org/0009-0009-6812-5540","observed_orcids":["https://orcid.org/0009-0009-6812-5540"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Zinner","raw_affiliation_strings":["Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Kurzrock","raw_affiliation_strings":["University of California at San Diego Moores Cancer Center, San Diego, CA, USA","UNIVERSITY OF CALIFORNIA AT SAN DIEGO MOORES CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California at San Diego Moores Cancer Center, San Diego, CA, USA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]},{"raw_affiliation_string":"UNIVERSITY OF CALIFORNIA AT SAN DIEGO MOORES CANCER CENTER","institution_ids":["https://openalex.org/I4390039236"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"D. S. Hong","raw_affiliation_strings":["Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Investigational Cancer Therapeutics (Phase I Program), Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 455, Houston, TX, 77030, USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5026095888"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.01725648,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"76","issue":"3","first_page":"597","last_page":"603"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.548799991607666,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.548799991607666,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.2655999958515167,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.07320000231266022,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pazopanib","display_name":"pazopanib","score":1.0},{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":1.0},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7829999923706055},{"id":"https://openalex.org/keywords/intermittent-dosing","display_name":"intermittent dosing","score":0.906000018119812},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.7710000276565552},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7929999828338623},{"id":"https://openalex.org/keywords/vegfr-inhibition","display_name":"VEGFR inhibition","score":0.7950000166893005},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.8960000276565552},{"id":"https://openalex.org/keywords/c-met","display_name":"c-Met","score":0.902999997138977},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.9350000023841858},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8600000143051147},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.7639999985694885},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.597000002861023},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.40700000524520874}],"concepts":[{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.9761325120925903},{"id":"https://openalex.org/C2778439243","wikidata":"https://www.wikidata.org/wiki/Q7157043","display_name":"Pazopanib","level":4,"score":0.9711669087409973},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8040216565132141},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7463545799255371},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7210405468940735},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6583731174468994},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6225352883338928},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.5386372208595276},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4268903434276581},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42012232542037964},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.37616828083992004},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.2226317822933197},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.12439754605293274},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.06914022564888}],"mesh":[{"descriptor_ui":"D000077341","descriptor_name":"Lapatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005784","descriptor_name":"Gene Amplification","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007191","descriptor_name":"Indazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019859","descriptor_name":"Proto-Oncogene Proteins c-met","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s00280-015-2824-6","doi":"https://doi.org/10.1007/s00280-015-2824-6","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-015-2824-6","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmid:26210681","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26210681","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"sustainable_development_goals_aurora":[{"display_name":"Zero hunger","id":"https://metadata.un.org/sdg/2","score":0.550000011920929}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W31557638","https://openalex.org/W1964407943","https://openalex.org/W1968626722","https://openalex.org/W1993739082","https://openalex.org/W2013856117","https://openalex.org/W2026519765","https://openalex.org/W2032037224","https://openalex.org/W2034801324","https://openalex.org/W2049792735","https://openalex.org/W2102995554","https://openalex.org/W2109117547","https://openalex.org/W2117692326","https://openalex.org/W2124003148","https://openalex.org/W2152142449","https://openalex.org/W2156078931","https://openalex.org/W2170781431"],"related_works":["https://openalex.org/W2026519765","https://openalex.org/W1981403915","https://openalex.org/W2590278846","https://openalex.org/W1980177367","https://openalex.org/W2947922406","https://openalex.org/W2108570128","https://openalex.org/W2063857096","https://openalex.org/W2148829218","https://openalex.org/W2168635453","https://openalex.org/W7099836647"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}